Rare Oncology News
Advertisement
Spotlight On
Olfactory Neuroblastoma
Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses
Prevalence
< 1 / 1,000,000
Age of Onset
ICD-10
C30.0
Inheritance
This condition does not appear to have a clear pattern of inheritance.
5 Facts you should know
FACT
A rare cancer of the upper part of the nasal cavity
FACT
It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses
FACT
Is of neurocrest origin, arising from olfactory sensory cells in the olfactory epithelium
FACT
The most common signs and symptoms are nasal obstruction (70%) and epistaxis (50%)
FACT
It is a slow developing but malignant tumor with high recurrence rates because of its anatomical position
Interest over time
Google searches
Common signs & symptoms
Loss of smell (anosmia)
Chronic sinus infections (sinusitis)
Nasal bleeding
Nasal discharge
Pain
Sinus pain and headache
Visual changes
Ear pain
Current treatments
A surgical removal of the tumor
Radiation therapy
Top Clinical Trials
Title | Description | Phases | Status | Interventions | More Information |
---|---|---|---|---|---|
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). | Olfactory neuroblastoma (ONB) is a rare cancer of the nasal cavity. At diagnosis, it is usually locally advanced. It tends to spread to the neck. Sometimes it spreads to the lungs and bones. Researchers want to find a better way to treat it. Objective: To learn if giving immunotherapy drug bintrafusp alfa can help ONB shrink or disappear. | Phase 2 | Not yet recruiting | Drug: Bintrafusp alfa / M7824 | More Info |
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages | This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy. | Phase 2 | Active, not recruiting | Drug: Cisplatin|Radiation: Adjuvant Proton Radiotherapy|Procedure: Endoscopic Resection|Drug: cisplatin and etoposide | More Info |
Top Treatments in Research
Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
---|---|---|---|---|---|
Bintrafusp alfa / M7824 | Bintrafusp alfa is a bifunctional fusion protein designed to simultaneously block two immunosuppressive pathways, TGF-β and PD-L1, within the tumor microenvironment. This bifunctional approach is thought to control tumor growth by potentially restoring and enhancing anti-tumor responses. | Phase 2 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | More Info | More Info |
18F-fludeoxyglucose (18F-FDG)/18F-FPPRGD2 | a radiopharmaceutical agent used in positron emission tomographic (PET) imaging. | Phase 1|Phase 2 | Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University | More Info | More Info |
doxorubicin hydrochloride|gemcitabine hydrochloride | Both gemcitabine diphosphate (dFdCTP) and gemcitabine triphosphate (dFdCTP) inhibit processes required for DNA synthesis. Incorporation of dFdCTP into DNA is most likely the major mechanism by which gemcitabine causes cell death. Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation- ... | Phase 2 | Medical University of South Carolina | More Info | More Info |
Cisplatin|Radiation: Adjuvant Proton Radiotherapy|Procedure: Endoscopic Resection|Drug: cisplatin and etoposide | A new treatment paradigm for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy. | Phase 2 | Memorial Sloan Kettering Cancer Center | More Info | More Info |
Doxepin hydrochloride | Doxepin is a tricyclic antidepressant that widely used in the therapy of depression. Doxepin can cause mild and transient serum enzyme elevations but is a rare cause of clinically apparent acute cholestatic liver injury. A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors. | Phase 3 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | More Info | More Info |